Drug Trial Radar · NCT02754297
Personalized PRRT of Neuroendocrine Tumors
Last checked: Nov 19, 2026Latest source record: Aug 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
275
Actual
Start
Apr 12, 2016
Primary completion
Apr 12, 2025
Study completion Apr 12, 2029
Sponsor
- Lead sponsor
- CHU de Quebec-Universite LavalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Apr 28, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In this study, peptide receptor radionuclide therapy (PRRT) with 177Lu-Octreotate (LuTate) will be personalized, i.e. administered activity of LuTate will be tailored for each patient to maximize absorbed radiation dose to tumor, while limiting that to healthy organs. The purpose of this study is to: * Assess the objective (radiological), symptomatic and biochemical response rates following an induction course of personalized PRRT; * Assess the overall, the disease-specific, and the progression-free survival following P-PRRT; * Correlate therapeutic response and survival with tumor absorbed radiation dose; * Evaluate the acute, subacute and chronic adverse events following P-PRRT; * Correlate toxicity (i.e. occurence and severity of adverse events) with absorbed radiation doses to organs at risk; * Optimize the quantitative SPECT imaging-based dosimetry methods in a subset of 20 patients (sub-study funded by the Canadian Institutes of Health Research). This study also has a compassionate purpose, which is to provide access to PRRT to patients.
Conditions
- Neuroendocrine Tumors
- Carcinoid Tumor
- Carcinoma, Neuroendocrine
Interventions
177Lu-OctreotateDrug
* The induction course will consist in 4 cycles at 8-10 weeks intervals. * Concomitant amino acids will be administered for renal protection. * Intra-arterial LuTate administration will be allowed in suitable cases. * Dosimetry will be based on quantitative SPECT/CT imaging. * In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: 3 months after induction course
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CHU de Québec - Université Laval
Québec, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.